Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Axcel and Accru Partners in connection with the acquisition of Sporrong & Eriksson Revisionsbyrå AB
Mandate

Vinge advises Axcel and Accru Partners in connection with the acquisition of Sporrong & Eriksson Revisionsbyrå AB

February 12, 2025 M&A Employment and Benefits Banking and Finance Commercial Agreements IT, Telecommunications and Outsourcing Intellectual Property Data protection and processing of personal data Real Estate and Construction Financial Regulatory

Vinge has advised Axcel VII and Accru Partners in connection with the acquisition of Sporrong & Eriksson Revisionsbyrå AB.

Sporrong & Eriksson Revisionsbyrå AB is an entrepreneur-led, local business with expertise in accounting, audit, tax, acquisition and advisory services. After the acquisition, Accru Partners consists of 28 independent firms within the aforementioned business areas.

Vinge’s team consisted of Christina Kokko, Egil Svensson, Michella Lina Said and Chris Bastholm (M&A), Narin Melazade and Simon Söderholm (Employment), Sofia Haggren (Banking and Finance), Mario Saad (Commercial Agreements), Elis Allmark (IT), Rebecka Målquist (Intellectual Property), Nicklas Thorgerzon (GDPR), Madelene Andersson (Real Property), Jonna Bondemark (Regulatory), Gulestan Ali and Jonna Fransson (Compliance) and Jessica Öijer (Transaction Support Coordinator).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025